Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Matthias J. Löhr

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7647-198X; OpenAlex author ID A5059085651, A5067118869, A5140952530. Sources: OpenAlex.

Their work

Papers
79 (first author 4, last author 15)
Trials
0
Grants
0
Labs led
2
Collaborators
231
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: 3 papers · 2015: 6 papers · 2016: 2 papers · 2017: 7 papers · 2018: 3 papers · 2019: 7 papers · 2020: 5 papers · 2021: 13 papers · 2022: 5 papers · 2023: 4 papers · 2024: 5 papers · 2025: 7 papers · 2026: 7 papers

Papers 50 of 79

  1. DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer. Co-author DOI 10.1002/advs.202417606↗
  2. Risk of Pancreatic Cancer Associated With Precursor Lesions in Individuals and First-Degree Relatives: A Nationwide Cohort Study. Co-author DOI 10.1016/j.cgh.2026.06.009↗
  3. Association between pancreatic enzyme replacement therapy and mortality in pancreatic cancer: a matched case-control study. Co-author DOI 10.1016/j.pan.2025.12.008↗
  4. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  5. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
  6. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  7. Unveiling sex differences in pancreatic ductal adenocarcinoma: Current evidence and future directions (Review). Co-author DOI 10.3892/ijo.2026.5848↗
  8. Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk. Co-author DOI 10.1002/ijc.35397↗
  9. Performance of MRI-based surveillance for high-risk individuals for pancreatic cancer. Co-author DOI 10.1016/j.ejrad.2025.112275↗
  10. High prevalence of pancreatic steatosis in pancreatic cancer patients: A meta-analysis and systematic review. Co-author DOI 10.1016/j.pan.2024.11.010↗
  11. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  12. Exploring the psychological burden in a pancreatic cancer surveillance programme based on high-risk individuals: a Swedish cross-sectional study. Last author DOI 10.1136/bmjopen-2024-097814↗
  13. Early Detection of Sporadic Pancreatic Cancer Last author DOI 10.1159/000545424↗
  14. Risk of Pancreatic Cancer in Inflammatory Pancreatic Diseases. Co-author DOI 10.4166/kjg.2025.019↗
  15. Can our experience with surveillance for inherited pancreatic cancer help to identify early pancreatic cancer in the general population? Co-author DOI 10.1007/s10689-024-00363-6↗
  16. Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer. Last author DOI 10.1016/j.esmogo.2024.100070↗
  17. Genderized Gut and Oral Microbiome Shifts: Uncovering Sex-Specific Dysbiosis in Pancreatic Cancer Co-author DOI 10.1101/2024.10.02.616338↗
  18. Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0405↗
  19. The Crosstalk Analysis between mPSCs and Panc1 Cells Identifies CCN1 as a Positive Regulator of Gemcitabine Sensitivity in Pancreatic Cancer Cells. Co-author DOI 10.3390/ijms25179369↗
  20. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide re… Co-author DOI 10.1016/j.pan.2022.12.003↗
  21. Artificial Intelligence in Pancreatic Ductal Adenocarcinoma Imaging: A Commentary on Potential Future Applications. Last author DOI 10.1053/j.gastro.2023.04.003↗
  22. Plasma thymidine kinase activity as a prognostic biomarker in pancreatic ductal adenocarcinoma: a single-center prospective study. Last author DOI 10.1080/00365521.2023.2198057↗
  23. Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Tr… Co-author DOI 10.2967/jnumed.123.265481↗
  24. Hereditary pancreatic cancer. Co-author DOI 10.1016/j.bpg.2021.101783↗
  25. Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. Co-author DOI 10.1016/j.isci.2022.105317↗
  26. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal ad… Co-author DOI 10.1016/j.pan.2022.04.007↗
  27. Cellular heterogeneity in pancreatic cancer: the different faces of gremlin action. First author DOI 10.1038/s41392-022-01203-8↗
  28. Pancreatic Cancer From the Patient Perspective: The Time to Act is Now. Co-author DOI 10.1177/23743735221112633↗
  29. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33464↗
  30. Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. Co-author DOI 10.1002/jev2.12142↗
  31. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. First author DOI 10.1002/ueg2.12123↗
  32. Stabilization of the classical phenotype upon integration of pancreatic cancer cells into the duodenal epithelium. Co-author DOI 10.1016/j.neo.2021.11.007↗
  33. Pancreatic cancer in patients with autoimmune pancreatitis: A scoping review. Last author DOI 10.1016/j.pan.2021.03.007↗
  34. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.07.009↗
  35. 3D heterospecies spheroids of pancreatic stroma and cancer cells demonstrate key phenotypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2021.101107↗
  36. Pancreatic cancer cachexia: three dimensions of a complex syndrome. Last author DOI 10.1038/s41416-021-01301-4↗
  37. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Co-author DOI 10.1097/cej.0000000000000588↗
  38. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Co-author DOI 10.1136/gutjnl-2019-319990↗
  39. Gastric Mucosal Abnormality and Risk of Pancreatic Cancer: A Population-Based Gastric Biopsy Cohort Study in Sweden. Co-author DOI 10.1158/1055-9965.epi-21-0580↗
  40. Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.21.00024↗
  41. Pancreatic Ductal Adenocarcinoma: Preclinical in vitro and ex vivo Models. Co-author DOI 10.3389/fcell.2021.741162↗
  42. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  43. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  44. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Co-author DOI 10.1158/1055-9965.epi-19-1027↗
  45. Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis. Co-author DOI 10.1159/000502844↗
  46. Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis. Last author DOI 10.3390/jcm9113720↗
  47. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. Co-author DOI 10.1002/ijc.31866↗
  48. Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2019.09.005↗
  49. Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-019-38603-w↗
  50. Palliative therapy in pancreatic cancer-interventional treatment with stents. Last author DOI 10.21037/tgh.2019.01.05↗

Closest collaborators

The 25 strongest of 231 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Miroslav Vujasinović · 9 shared papers, 2017–2026 · strength 2.14
  2. Rainer Lothar Heuchel · 16 shared papers, 2011–2024 · strength 1.82
  3. Poya Ghorbani · 8 shared papers, 2020–2026 · strength 1.58
  4. Carlos Fernández Moro · 10 shared papers, 2017–2025 · strength 1.44
  5. Maximilian Kordes · 10 shared papers, 2019–2024 · strength 1.34
  6. Núria Malats · 11 shared papers, 2017–2025 · strength 1.06
  7. Caroline Sophie Verbeke · 13 shared papers, 2015–2023 · strength 0.97
  8. Patrick Maisonneuve · 5 shared papers, 2020–2025 · strength 0.94
  9. Ernesto Sparrelid · 5 shared papers, 2021–2024 · strength 0.92
  10. Daniel Öhlund · 3 shared papers, 2024–2026 · strength 0.81
  11. Francisco X. Real · 10 shared papers, 2015–2025 · strength 0.79
  12. Ebba Asplund · 3 shared papers, 2023–2025 · strength 0.76
  13. Maria Gustafsson Liljefors · 4 shared papers, 2019–2026 · strength 0.75
  14. Alfredo Carrato · 9 shared papers, 2017–2025 · strength 0.74
  15. Marco Del Chiaro · 8 shared papers, 2015–2021 · strength 0.73
  16. Jorg H. Kleeff · 9 shared papers, 2015–2025 · strength 0.67
  17. Luis Muñoz‐Bellvís · 8 shared papers, 2017–2025 · strength 0.62
  18. J. Enrique Domínguez‐Muñoz · 8 shared papers, 2017–2025 · strength 0.62
  19. William Greenhalf · 8 shared papers, 2017–2025 · strength 0.62
  20. Tatjana Crnogorac‐Jurcevic · 8 shared papers, 2017–2025 · strength 0.62
  21. Thomas Mathias Gress · 8 shared papers, 2017–2025 · strength 0.62
  22. Nikolaos Kartalis · 5 shared papers, 2015–2025 · strength 0.62
  23. Jingru Yu · 6 shared papers, 2019–2021 · strength 0.62
  24. Raffaella Pozzi Mucelli · 4 shared papers, 2015–2025 · strength 0.60
  25. Weimin Ye · 7 shared papers, 2015–2021 · strength 0.59

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.